Robotic Surgery For Endometrial Cancer Market: Current Analysis and Forecast (2025-2033)

Robotic Surgery for Endometrial Cancer Market Size & Forecast

The Robotic Surgery for Endometrial Cancer Market was valued at approximately USD 173.8 million in 2024 and is expected to grow at a substantial CAGR of around 15.8% during the forecast period (2025-2033), owing to technological advancements in robotic surgical systems.

Robotic Surgery for Endometrial Cancer Market Analysis

Robotic surgery for endometrial cancer represents a cutting-edge and minimally invasive approach to the treatment of this gynecologic malignancy. Utilizing advanced robotic technology, this technique enables highly precise and intricate procedures with enhanced visualization and dexterity, surpassing the limitations of traditional laparoscopic surgery. The procedure involves a skilled surgeon controlling robotic arms equipped with miniature instruments, facilitating access to hard-to-reach areas while minimizing incision size. As a result, patients experience reduced postoperative pain, shorter hospital stays, and quicker recovery times. The developing healthcare infrastructure, along with the integration of advanced technology with the healthcare systems, are the major contributing factors for the market growth of robotic surgery for endometrial cancer. Systems such as Medtronic’s Hugo RAS systems are designed to make robotic-assisted surgery more possible. These systems provide modular, portable, enhanced visualization, and instrumentation to surgeons. The ease of surgery and increased preference for advanced surgical systems such as Hugo RAS by surgeons are the major factors responsible for the growth of robotic surgery for endometrial cancer in the nation. 

Robotic Surgery for Endometrial Cancer Market Trends

This section discusses the key market trends influencing the various segments of the Robotic Surgery for Endometrial Cancer Market as identified by our research experts.

Shift Toward Minimally Invasive Procedures

There is an increasing and continuous tendency to perform endometrial cancer surgeries with minimal invasiveness, and this is because the patients and medical practitioners nowadays prefer undergoing procedures that are not very invasive and that can be done in a short duration of time and with minimal complications such as those that would require a longer stay in the hospital. Hysterectomy and lymphadenectomy are examples of MARS, which are used frequently due to better vision, better control, and better position of the surgeon, providing better results. This trend is further fueled by the escalating awareness of the advantages of minimization of invasive procedures, emerging evidence of clinical recommendations, and the growing customer-oriented approach to health care with a focus on the time to recover and quality of life.

Robotic Surgery for Endometrial Cancer Industry Segmentation

This section provides an analysis of the key trends in each segment of the global Robotic Surgery for Endometrial Cancer Market report, along with forecasts at the global, regional, and country levels for 2025-2033.

The Maintenance Services Segment Holds the Largest Share of the Robotic Surgery for Endometrial Cancer Market.

Based on components, the market is segmented into robotic surgery systems and maintenance services. Among them, the maintenance services segment is expected to grow to a higher CAGR during the forecast period. The maintenance services are expected to grow with a higher CAGR. The increasing adoption of the robotic surgery system that requires maintenance services for better operation is the major reason for the fast growth of maintenance services during the forecast period. The services, such as preventive maintenance, repairs & replacements, software upgrades, and system optimization, play a crucial role in ensuring the long-term reliability, safety, and performance of these advanced surgical technologies, thereby benefiting patients undergoing robotic surgery for endometrial cancer.  As a result, the maintenance service segment is expected to witness growth with a higher CAGR during the forecast period.

The Laser Surgery Market is Expected to Witness a Higher CAGR than the Robotic Surgery for Endometrial Cancer Market.

Based on surgery type, the market is segmented into cryosurgery, laser surgery, hysterectomy, trachelectomy, and others. Among them, the laser surgery segment is expected to grow with a higher CAGR during the forecast period. Laser surgery is a minimally invasive technique that uses a high-energy laser beam to precisely remove or destroy tissue. Laser surgery can minimize damage to surrounding healthy tissue, which can lead to faster healing and less pain compared to traditional surgical techniques. Additionally, laser surgery can be used to precisely target and remove cancerous tissue, which can improve the chances of complete removal of the cancer. Further, the increased product launches and research & development in robot-assisted laser surgeries are the major attributing factors for the growth of the market. For instance, Researchers at the National Robotarium, a partnership between Heriot-Watt University and the University of Edinburgh, industry partners, and Edinburgh-based clinicians are developing laser-based novel robotic surgical techniques to improve surgical outcomes and patient care in cancer. The breakthrough method was awarded USD 1.59 million and was funded by the Engineering and Physical Sciences Research Council, part of UK Research and Innovation.

Asia Pacific has a significant share of the market in 2024.

Asia Pacific is expected to grow with the highest CAGR Robotic Surgery for Endometrial Cancer market during the forecast period. The market growth in this region is attributed to factors such as an increasing prevalence of endometrial cancer, rising awareness of robotic surgical options, improvements in healthcare infrastructure, and the adoption of advanced medical technologies. Furthermore, the region is also witnessing rapidly increasing cases of uterine cancer is a major factor in the market growth of robotic surgery for endometrial cancer in the Asia-Pacific. For example, according to WHO, each year, more than 2.3 million people are diagnosed with cancer in the South East Asia Region, and about 1.4 million die of the disease.

China Dominates the APAC Robotic Surgery for Endometrial Cancer Market

The robotic surgery market for eradicating endometrial cancer is rapidly growing in China due to the government’s support for technology advancements in the healthcare sector. The guidelines, including “Made in China 2025” and “Development Plan of Medical Equipment Industry”, help the development of surgical robotics through promotion of Chinese innovation, investment, as well as the speeding up of the approval processes. The utilisation of robotic surgeries, including hysterectomy and lymphadenectomy, is on the rise due to enhanced awareness of minimally invasive procedures, advanced artificial intelligence, and 5G connected surgical systems, development of considerably cheaper domestic robotic systems. These variables are collectively contributing to the development of China as a centre for innovative treatment of gynecologic cancer using the robotic methodology.

Robotic Surgery for Endometrial Cancer Industry Competitive Landscape  

The Robotic Surgery for Endometrial Cancer Market is competitive, with several global and international players. The key players are adopting different growth strategies to enhance their market presence, such as partnerships, agreements, collaborations, new product launches, geographical expansions, and mergers and acquisitions.

Top Robotic Surgery for Endometrial Cancer Companies

Some of the major players operating in the market are Intuitive Surgical; Stryker; Accuray Incorporated; NuVasive, Inc; Smith+Nephew; Asensus Surgical US, Inc.; Medtronic; Auris Health, Inc.; Siemens Healthcare GmbH; and Renishaw plc.

Recent Developments in the Robotic Surgery for Endometrial Cancer Market

• In August 2024, GSK plc announced U.S. FDA approval of Jemperli (dostarlimab) plus chemotherapy for all adult patients with primary advanced or recurrent endometrial cancer. This strategic launch helped the company to strengthen its product portfolio and enhance its revenue growth.

• In June 2024, AstraZeneca’s Imfinzi in combination with carboplatin and paclitaxel has been approved in the U.S. for adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient. This approval helped the company to broaden its product portfolio and generate revenue.

Robotic Surgery for Endometrial Cancer Market Report Coverage

Reasons to Buy the Robotic Surgery for Endometrial Cancer Market Report:

• The study includes market sizing and forecasting analysis validated by authenticated key industry experts.

• The report presents a quick review of overall industry performance at a glance.

• The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolios, expansion strategies, and recent developments.

• Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.

• The study comprehensively covers the market across different segments.

• Deep dive regional-level analysis of the industry.

Customization Options:

The global robotic surgery for endometrial cancer market can be customized further as per the requirement or any other market segment. Besides this, UnivDatos understands that you may have your own business needs; hence, feel free to contact us to get a report that completely suits your requirements.